Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today

被引：2
|
作者：
Bloomgarden, Zachary T. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2019年 / 157卷
关键词：
DIPEPTIDYL-PEPTIDASE-IV; ALL-CAUSE MORTALITY; CARDIOVASCULAR EVENTS; METAANALYSIS; SITAGLIPTIN; RISK;
D O I：
10.1016/j.diabres.2019.107906
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Comparison of the Efficacy and β-Cell Function In DPP-IV Inhibitors Treated Type 2 Diabetes Patients between Asian and Caucasian
    Cai, Xiaoling
    Han, Xueyao
    Luo, Yingying
    Ji, Linong
    DIABETES, 2013, 62 : A667 - A667
  • [22] GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors
    Ahrén B.
    Current Diabetes Reports, 2007, 7 (5) : 340 - 347
  • [23] Combination of monoclonal antibodies and DPP-IV inhibitors in the treatment of type 1 diabetes: A plausible treatment modality?
    Dubala, Anil
    Gupta, Ankur
    Samanta, Malay K.
    MEDICAL HYPOTHESES, 2014, 83 (01) : 1 - 5
  • [24] Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes
    Hernandez, Cristina
    Bogdanov, Patricia
    Sola-Adell, Cristina
    Sampedro, Joel
    Valeri, Marta
    Genis, Xavier
    Simo-Servat, Olga
    Garcia-Ramirez, Marta
    Simo, Rafael
    DIABETOLOGIA, 2017, 60 (11) : 2285 - 2298
  • [25] Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes
    Cristina Hernández
    Patricia Bogdanov
    Cristina Solà-Adell
    Joel Sampedro
    Marta Valeri
    Xavier Genís
    Olga Simó-Servat
    Marta García-Ramírez
    Rafael Simó
    Diabetologia, 2017, 60 : 2285 - 2298
  • [26] Synthetic and phytocompounds based dipeptidyl peptidase-IV (DPP-IV) inhibitors for therapeutics of diabetes
    Singh, Anand-Krishna
    Jatwa, Rameshwar
    Purohit, Ashok
    Ram, Heera
    JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH, 2017, 19 (10) : 1036 - 1045
  • [27] Assessment of Changes in Dipeptidyl-peptidase-IV (DPP-IV) Enzyme Activity in Type 1 and Type 2 Diabetes
    Stevenson, C. L.
    Abdel-Wahab, Y. H. A.
    O'Kane, M. J.
    McKillop, A. M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 : S344 - S344
  • [28] Sixteen-Years of Clinically Relevant Dipeptidyl Peptidase-IV(DPP-IV) Inhibitors for Treatment of Type-2 Diabetes: A Perspective
    Kushwaha, R. N.
    Haq, W.
    Katti, S. B.
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (35) : 4013 - 4045
  • [29] Incretin mimetics and DPP-IV inhibitors: New paradigms for the treatment of type 2 diabetes (vol 19, pg 612, 2006)
    Hinnen, D.
    Nielsen, L. L.
    Waninger, A.
    Kushner, P.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2007, 20 (02) : 240 - 240
  • [30] Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: For GLP-1/DPP-IV inhibitors
    Kumar, Ajay
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2012, 28 : 21 - 25
12345